One popular new game in biotech investment circles is guessing the cancer vaccine developer that is most likely to follow in the footsteps of Dendreon (NASDAQ: DNDN), which braved some considerable challenges to bring Provenge to the market. But Trista Morrison at BNET dashes the fevered speculation with a bucket of cold water, noting that the road to Provenge's approval was littered with the burned wreckage of failed rivals. This is an extremely complex field that didn't get any easier to work in now that Provenge is coming to the market. And the second approval will require long years of development work. Report